EMA: IN REGULATORS’ VIEW, COS SHOULD EXPLORE FEASIBILITY OF DEVELOPING BIVALENT OR MULTIVALENT VARIANT VACCINES TO DETERMINE IF THEY OFFER ADVANTAGES TO MONOVALENT VACCINES